肝细胞癌的综合介入治疗

肝细胞癌（HCC）是世界范围内第五大常见肿瘤，每年新增病例超过50万。由于HCC早期症状隐匿，大多数患者在确诊时已是中晚期，失去了接受治愈性治疗的机会。而中晚期HCC患者由于肝功能损伤及肿瘤进展致预后很差，目前，以肝动脉栓塞化疗术（TACE）为主的综合介入治疗已成为中晚期HCC的主要治疗方式。本文就HCC的综合介入治疗的最新进展综述如下。

Comprehensive intervention treatment for hepatocellular carcinoma

Hepatocellular carcinoma （ HCC ） is the fifth most common cancer in the world and more than half a million new cases are reported each year. Due to the absence of clinical symptoms in the early stage, the majority of patients are diagnosed at the intermediate/advanced stage when curative treatment options are limited. The prognosis of patients with intermediate/advanced HCC is poor because of the high potential for liver function damage and tumor progression. Combination therapies involving transarterial chemoembolization （TACE） have become the main treatments used in intermediate/advanced HCC. This comprehensive review discusses the latest progress in research of interventional treatments for HCC and their implications for the intermediate/advanced HCC patients particularly.